Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

HeartWare secondary offering grosses $62.8 million: Ventricular assist device developer grosses $62.8 million from a secondary offering of 1.77 million shares of common stock at $35.50 per share, completed Feb. 2. HeartWare International plans to use the proceeds for "general corporate and working capital purposes," the company states. The firm's HeartWare miniature ventricular assist system with HVAD pump is being assessed in a 150-patient U.S. trial for use as a bridge to transplant, and the company expects to begin a pivotal study in mid-2010 for use as an alternative to transplant (1"The Gray Sheet" Dec. 7, 2009). The underwriters for the stock offering included JP Morgan Securities, Canaccord Adams, Lazard Capital Markets and Wedbush PacGrow Life Sciences
Advertisement

Related Content

Piper Jaffray Healthcare Conference In Brief
Piper Jaffray Healthcare Conference In Brief

Topics

Advertisement
UsernamePublicRestriction

Register

MT028492

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel